Friday, 6 January 2012

Greeks Reeling From Health Care Cutbacks

AppId is over the quota
AppId is over the quota

Four days earlier, she had run out of insulin and, without insurance and unable to pay for more, she had gone from drugstore to drugstore, pleading for at least enough for a few days. It took her three hours to find a pharmacist who was willing to help.

“I tried a lot of them,” she said, gazing at the floor.

Greece used to have an extensive public health care system that pretty much ensured that everybody was covered for everything. But in the last two years, the nation’s creditors have pushed hard for dramatic cost savings to cut back the deficit. These measures are taking a brutal toll on the system and on the country’s growing numbers of poor and unemployed who cannot afford the new fees and co-payments instituted at public hospitals as part of the far-reaching austerity drive.

At public hospitals, doctors report shortages of all kinds of supplies, from toilet paper to catheters to syringes. Computerized equipment has gone unrepaired and is no longer in use. Nurses are handling four times the patients they should, and wait times for operations — even cancer surgeries — have grown longer.

Access to drugs has also been affected, as some drug manufacturers, owed tens of millions of dollars, are no longer willing to supply Greek hospitals. At the same time pharmacists, afraid that the government might not reimburse them, are asking for cash payments, even from those with insurance.

Many experts say that Greece’s public health system was bloated and corrupt and in dire need of reform. But they say also that the cuts have been so deep and have come so fast, that they have hit like a tsunami.

In just two years, the government has cut spending on health care to $17 billion from $19.5 billion — a 13 percent decrease. And under its agreement with its creditors, Greece must find even more health care savings next year — as much as $915 million, government officials said.

At the same time, public health facilities have seen a 25 to 30 percent increase in patients because so many Greeks can no longer afford to visit private clinics.

Dr. Olatz Ugarte, an anesthesiologist at the Saint Savvas Cancer Hospital in Athens, said that breast cancer patients often have to wait three months now to have tumors removed. “Waiting that long can be life or death for these patients,” she said.

In a recent letter to the medical journal The Lancet, a team of English researchers warned that a “Greek tragedy” could be in the making, pointing to rising suicide and H.I.V. rates and deterioration of services at hospitals under financial pressure. “In an effort to finance debts,” the researchers said, “ordinary people are paying the ultimate price: losing access to care and preventive services, facing higher risks of H.I.V. and sexually transmitted diseases, and in the worst case losing their lives.”

At the Perama clinic, which is run by the international nonprofit Doctors of the World, doctors say they are seeing many families that cannot afford bus fare, let alone the new $6.50 fee at public clinics.

Technically, those Greeks who cannot pay are entitled to free care. But the bureaucracy can be overwhelming. Ms. Ragamb, a former hairdresser whose unemployment benefits and health insurance ran out six months ago, said she was still waiting to get the right papers.

The story did not surprise Dr. Liana Mailli, the pediatrician who was seeing Ms. Ragamb’s son, Elias. The 3-year-old got a diagnosis of diabetes only a few months ago, after he fell into a coma. Dr. Mailli has heard of such bureaucratic troubles from many patients. Even more often, she said, parents have fallen behind in paying their health insurance contributions, or their employers do not pay and so they are no longer covered.

One development that Dr. Mailli said she found particularly disturbing was that a growing number of children had not had their basic vaccinations.

If nothing is done, she said, polio, diphtheria and whooping cough could all return to Greece. “This is such a serious thing,” she said. “But these vaccines are expensive.”

At the start of its debt crisis, Greece was spending about 6 percent of its G.D.P. on health care — about average for Europe. But the system was far from efficient. It includes many small hospitals and a reliance on expensive brand name drugs.

Moreover, there was widespread corruption. Experts say doctors often had lucrative deals with drug manufacturers that led them to vastly overprescribe, and many expected cash payments on the side for timely and attentive care.

Since the debt crisis began in 2009, the government has frozen hiring, cut salaries and focused on tracking prescriptions and new procurement procedures. About 20 doctors have been arrested for corruption.

But little has gone smoothly.

Government officials acknowledge some problems, but say that the system was simply unsustainable. In the next year, they say, adjustments can be made.

“We have had two years of emphasis on the financial, now we will pass to evaluation,” said Nikos Polyzos, the secretary general of the Health Ministry.

But many doctors say the new emphasis on cutting costs has gone too far. In addition to shortages, they say that the supplies they do have are of poor quality. They complain that bugs have been found in new syringes imported from China, sutures fall apart and generic drugs do not seem to do the job. And the hiring freeze has caused such a shortage of nurses, some doctors said, that procedures frequently have to be postponed.

Dimitris Bounias and Nikolas Leontopoulos contributed reporting.


View the original article here

Personal Health: High Sodium-to-Potassium Ratio in Diet Is a Major Heart Risk

AppId is over the quota
AppId is over the quota

Well, think again. A major study, based on data from more than 12,000 American adults, took into account all those risk factors for death from heart disease. The researchers found that while a diet high in sodium — salt is the main source — increases your risk, even more important is the ratio of sodium (harmful) to potassium (protective) in one’s diet.

When people whose meals contained little sodium relative to potassium were compared with those whose diets had a high sodium-to-potassium ratio, the latter were nearly 50 percent more likely to die from any cause and more than twice as likely to die from ischemic heart disease during a follow-up period averaging 14.8 years.

Although there has been on-and-off controversy about the value of limiting dietary salt, there is no question that a high level of sodium in the diet raises blood pressure and the risk of chronic hypertension by stiffening arteries and blocking nitric oxide, which relaxes arteries. Hypertension, in turn, contributes to heart disease and stroke, leading causes of death.

Potassium, on the other hand, activates nitric oxide and thus reduces pressure in the arteries, lowering the risk of hypertension.

“We controlled for all the major cardiovascular risk factors and still found an association between the sodium-potassium ratio and deaths from heart disease,” said Dr. Elena V. Kuklina, a nutritional epidemiologist at the Centers for Disease Control and Prevention and an author of the study, published earlier this year in Archives of Internal Medicine. “With age, the risk of high blood pressure increases. The lifetime risk in this country is 90 percent. If you live long enough, you’re at risk.”

According to an Institute of Medicine report on sodium released last year, “No one is immune to the adverse health effects of excessive sodium intake.”

Our High-Salt Diet

Ninety percent of the sodium in the American diet comes from salt, three-fourths of which is consumed in processed and restaurant foods. Salt added in home cooking and at the table accounts for only a minor proportion of sodium intake.

The body’s requirement for sodium is very low — only 220 milligrams a day — but the average American consumes more than 3,400 milligrams daily. The current Dietary Guidelines for Americans recommend a maximum of 2,300 milligrams (about a teaspoon of salt) for people over age 2, but only 1,500 milligrams for the 70 percent of adults at high risk of sodium-induced illness: people older than 50, all African-Americans, and everyone with high blood pressure, diabetes or chronic kidney disease.

Despite widespread efforts to get people to consume less sodium, intake of this nutrient has increased significantly since the early 1970s as consumption has risen of processed and restaurant foods, which rely heavily on salt as a cheap way to enhance flavor and texture and preserve food. Because salt is categorized by the Food and Drug Administration as G.R.A.S., or “generally recognized as safe,” there is no limit to the amount food producers can use in a product.

To make matters worse, not only does the amount of sodium rise precipitously when foods like tomatoes and potatoes are processed, but the natural potassium in these foods declines significantly, worsening the sodium-potassium ratio.

The profligate use of salt in foods prepared outside the home has created an American preference for a salty taste, a preference that can be reversed with no loss of consumer pleasure if done slowly, said Dr. Thomas A. Farley, commissioner of New York City’s Department of Health and Mental Hygiene.

His department is leading a national effort started in 2008 to get food producers and restaurants to gradually reduce the salt in their products. Thus far, 28 national food companies, retailers and supermarket chains, including Kraft, Subway, Target and Delhaize America, have made a commitment to the National Salt Reduction Initiative to cut sodium in their products by an average of 25 percent by 2014.

But Dr. Jane E. Henney, chairwoman of the committee that produced the Institute of Medicine report, said this is still just a voluntary effort, and to make a lasting nationwide difference in sodium intake, the government needs to push harder for change. The report said, “What is needed is a coordinated effort to reduce sodium in foods across the board by manufacturers and restaurants — that is, create a level playing field for the food industry.”

Dr. Henney, a public health specialist at the University of Cincinnati College of Medicine, said it is time to modify the G.R.A.S. status of salt because it can no longer be considered safe under current conditions of use. This would allow the Food and Drug Administration to place limits on the amounts of salt that can be used commercially in preparing various types of foods.

The report stated that “population-wide reductions in sodium could prevent more than 100,000 deaths annually.”

It can be done, if there is a will. Through decades of voluntary efforts and regulation, Finland managed to cut sodium intake by one-third, which has resulted in a decrease in hypertension and premature deaths from stroke and coronary heart disease.

What You Can Do

Dr. Kuklina recommends eating fewer processed foods, especially processed meats, and more fresh fruits and vegetables and dairy products that are low in sodium, like yogurt and milk. Increase your potassium intake not by taking supplements, but by eating more cantaloupe, bananas, oranges, grapes, grapefruit, blackberries, yogurt, dried beans, leafy greens, potatoes and sweet potatoes.

When ordering in a restaurant, she suggests, ask that your food be prepared without added salt and your vegetables steamed, and always request that salad dressings and sauces be served on the side, enabling you to use far less than the chef might. Consider splitting an order between two people, which would cut the salt intake in half. And if a dish arrives that is too salty, send it back to the kitchen.

Avoid fast-food restaurants, where a single meal can contain a day’s worth of sodium.

When shopping, Dr. Farley said, “read labels and compare products, then choose those with lower sodium.” He acknowledged that products labeled “low sodium” or “no added salt” can turn off consumers, who think they’ll be tasteless. But you can always add a modest amount of salt at the table.

He also suggested asking food companies to use less salt in your favorite products and supporting the government’s efforts to reduce sodium consumption by commenting on a proposal published on Sept. 15 in the Federal Register (Docket No. FDA-2011-N-0400 and Docket No. FSIS-2011-0014). The easiest way to comment is through the American Heart Association’s Web site: www.heart.org/sodium, then click on “Send your comment letter today.”


View the original article here

Vital Signs: Trace Elements and Levels of Pancreatic Cancer Risk

AppId is over the quota
AppId is over the quota

A new study has found that high bodily levels of the trace elements nickel and selenium may be associated with reduced risk for pancreatic cancer, and that high levels of arsenic, cadmium and lead may increase the risk.

The study, published online Dec. 19 in the journal Gut, included 118 pancreatic cancer patients and 399 patients with other diagnoses at several hospitals in Spain. Researchers analyzed toenail samples with plasma mass spectrometry, a highly sensitive technique for detecting trace elements.

After controlling for age, sex, smoking, diabetes and other factors, the scientists found that the subjects with the highest levels of arsenic were at twice the risk for pancreatic cancer, compared with those with the lowest concentrations. Those with high levels of cadmium were at three times the risk for pancreatic cancer, while those with the highest levels of lead were at six times the risk.

Those with the highest levels of nickel and selenium, on the other hand, were at significantly lower risk for pancreatic cancer.

Dr. NĂºria Malats, an epidemiologist at the Spanish National Cancer Research Center and the senior author of the new study, said that it was the first to provide these kinds of results with trace elements, and that it did not mean that people should take dietary supplements.


View the original article here

Recipes for Health: Turnips: Versatile and Nutritious in Any Season — Turnips: Versatile and Nutritious in Any Season

AppId is over the quota
AppId is over the quota

The turnips we get now are not sweet and tender like young spring turnips, which are almost a different vegetable altogether. They stand up to longer cooking times, so they’re perfect for soups, stews and gratins. But I found them equally welcome in a frittata and a stir-fry. I’ll be using the young ones next spring in tender vegetable braises, but for now I’m very happy with my robust winter turnips.

Couscous With Turnips and Sweet Potatoes

This spicy, comforting couscous demands little in the way of prep time. It’s the long simmer on the stove that results in the tasty broth. As it simmers, the sweet potato falls apart into small bits that tint the broth.

1 onion, chopped

1 leek, white and light green parts only, cut in thick slices and cleaned

4 large garlic cloves, minced

Salt, preferably kosher salt, to taste

2 teaspoons cumin seeds, lightly toasted and ground

1 teaspoon coriander seeds, lightly toasted and ground

1 teaspoon caraway seeds, lightly toasted and ground

1/2 teaspoon cayenne (more to taste)

A bouquet garni consisting of 8 sprigs each parsley and cilantro

1 tablespoon tomato paste

1 tablespoon harissa (more to taste), plus additional for serving

1 large sweet potato (about 10 ounces), peeled and cut in large dice

1 pound turnips, cut in wedges

1 large carrot, peeled and cut in thick slices

6 cups water

Salt to taste

1 can chickpeas, drained and rinsed, or 1 1/2 cups cooked chickpeas

1/2 cup chopped fresh parsley or cilantro, or a combination

1 1/2 to 2 cups couscous, preferably whole-wheat couscous (1/4 to 1/3 cup unreconstituted couscous per person)

1. Combine all the ingredients except the chickpeas and chopped parsley or cilantro and bring to a boil. Reduce the heat to low, cover and simmer for 1 hour. Taste and adjust salt. The stew should be spicy and flavorful. Stir in the chickpeas and parsley or cilantro and heat through.

2. Reconstitute and steam the couscous. Serve the couscous in wide bowls or mound onto plates and top with the stew and a generous amount of broth. Pass more harissa at the table.

Yield: 6 servings.

Advance preparation: The stew can be made a day ahead and reheated. Leftovers will keep for 3 or 4 days in the refrigerator. The couscous can be reconstituted up to a day ahead, then steamed before serving.

Nutritional information per serving: 363 calories; 0 grams saturated fat; 1 gram polyunsaturated fat; 1 gram monounsaturated fat; 0 milligrams cholesterol; 76 grams carbohydrates; 14 grams dietary fiber; 330 milligrams sodium (does not include salt to taste); 14 grams protein

Martha Rose Shulman is the author of “The Very Best of Recipes for Health.”


View the original article here

Pressure to Link Drugs and ‘Companion Diagnostics’

AppId is over the quota
AppId is over the quota

The Food and Drug Administration last year rejected the company’s drug to treat a subset of leukemia patients whose tumors had a particular genetic mutation. The main problem was not the drug itself, the agency said. Rather, ChemGenex had not specified a companion test that could reliably detect the mutation so that the drug could be given to the patients it is intended to help.

These days, it is often not enough for pharmaceutical companies simply to bring a drug to market. Regulators and insurers are also prodding the companies to develop tests to pinpoint which patients are most likely to benefit from a drug, thereby sparing other patients from needless side effects and expense.

The pressure has thrust drug and diagnostics companies into sometimes awkward partnerships aimed at developing such tests, which are called companion diagnostics. There were at least 25 such deals in 2010 and 15 in the first half of 2011, up from only seven in 2008, according to PricewaterhouseCoopers, a consulting firm.

“The tests are becoming almost gatekeepers to the drug,” said M. Trevor Page, director of business development at Dako, a Danish diagnostics company.

The F.D.A. issued guidance to the industry on companion diagnostics in July, including its preference for having the test ready for approval at the same time as the drug. The following month, as if to show how it should be done, it approved two drugs and their accompanying tests.

One of the drugs, Pfizer’s Xalkori for lung cancer, works wonders — but only for the roughly 5 percent of patients whose tumors have a particular chromosomal abnormality, as determined by a test from Abbott Laboratories.

The other drug, Zelboraf, from Roche and Plexxikon, can also produce remarkable improvements, but only for the roughly half of melanoma patients whose tumors have a particular mutation. The F.D.A. approved a test from Roche’s diagnostics division to detect that mutation.

But the simultaneous approval of new drugs and tests is still rare. Before August, the only other dual approval was of Genentech’s breast cancer drug Herceptin and Dako’s test for the related HER2 protein in 1998. There are more than 70 other tests that guide drug use in some way, according to the Personalized Medicine Coalition, but they are rarely required and often developed well after the drug reaches the market.

There are numerous economic, scientific and regulatory obstacles to developing companion diagnostics, executives and analysts say.

Often, scientists simply do not know what to test for to predict a drug’s effectiveness, or they don’t find out until near the end of the drug’s clinical trials. And coordinating development and approval of a drug and a test — by two separate companies reviewed by two F.D.A. divisions — can raise the cost of drug development if not done well.

“This is like trying to choreograph a dance,” said Dr. Mace L. Rothenberg, who runs cancer clinical trials for Pfizer.

Moreover, it is often a dance between a giant and a pixie, locked in an embrace but with a tendency to move in opposite directions.

Pharmaceutical companies can spend hundreds of millions of dollars to develop a drug, then can reap billions of dollars a year in sales with high profit margins. Diagnostic companies typically spend several million dollars to develop a test, with annual revenues also around that level, and low profit margins.

“You are really trying to get two very disparate industries to understand each other,” said Mollie Roth, chief operating officer of Diaceutics, a consulting firm specializing in companion diagnostics.

For pharmaceutical companies, the risk is that a test can lower sales of their drugs by restricting use to a fraction of potential patients.

An often cited example of such a problem involved Selzentry, a Pfizer drug approved in 2007 to treat people with a certain subtype of H.I.V.

The test of a patient’s virus, offered by Monogram Biosciences, cost about $2,000, and all samples had to be sent to Monogram’s laboratory in California. Analysts say the cost and inconvenience of the testing deterred use of Selzentry, especially since it was competing with drugs that could be used by all patients, with no need for testing.

“Top management still sees companion diagnostics as an obstacle between their product and the market,” said Jorge Leon, a consultant to both drug and diagnostic companies.

Still, drug companies are embracing companion diagnostics because of pressures to control health spending. Also, in the rare cases where a test is available early in the drug’s development, as was the case with Xalkori and Zelboraf, clinical trials can be made smaller and less costly by restricting them to patients most likely to benefit from the drug.

For diagnostic companies, there is a risk of developing a test in advance for a drug that may never reach the market.


View the original article here

Vital Signs: Vitamins B, C, D and E and Omega-3 Strengthen Older Brains

AppId is over the quota
AppId is over the quota

Higher blood levels of omega-3 fatty acids, vitamin B, vitamin C, vitamin D and vitamin E are associated with better mental functioning in the elderly, a new study has found.

Researchers measured blood levels of these nutrients in 104 men and women, whose average age was 87. The scientists also performed brain scans to determine brain volume and administered six commonly used tests of mental functioning. The study is in the Jan. 24 issue of Neurology.

After controlling for age, sex, blood pressure, body mass index and other factors, the researchers found that people with the highest blood levels of the four vitamins scored higher on the cognitive tests and had larger brain volume than those with the lowest levels.

Omega-3 levels were linked to better cognitive functioning and to healthier blood vessels in the brain, but not to higher brain volume, which suggests that these beneficial fats may improve cognition by a different means.

Higher blood levels of trans fats, on the other hand, were significantly associated with impaired mental ability and smaller brain volume.

The lead author, Gene L. Bowman, a neurologist at Oregon Health and Science University, said that the study could not determine whether taking supplements of these nutrients would decrease the risk for dementia. But he added: “What’s the harm in eating healthier? Fish, fruits, vegetables all have these nutrients, and staying away from trans fats is one key thing you can do.”


View the original article here

EmblemHealth Could Become For-Profit, Bloomberg Says

AppId is over the quota
AppId is over the quota

The conversion of the insurer, EmblemHealth, which provides health coverage for most New York City public workers, would most likely provide at least $1 billion in one-time revenue for New York’s cash-hungry state government.

The Bloomberg administration has objected for years to such a move, saying it could drive up the city’s health insurance costs. But on Friday, although there was no evidence that a deal was imminent, the mayor said he had “no interest in stopping the governor from getting a billion dollars for the state budget.”

“We will find some way, I’m convinced,” Mr. Bloomberg said on his weekly radio program on WOR-AM (710). He added: “If it looks like a good deal for the city, or the city doesn’t get hurt — because we do get benefits when the state gets money because it stops them from cutting us back — we’re going to be there. And I think that’s the way it will work out.”

Emblem first initiated the process of becoming a for-profit company during the administration of Gov. Eliot Spitzer, and the State Legislature approved rules in 2007 on how such a conversion could take place.

The city unsuccessfully sued in federal court in an effort to block the merger of the two insurers that now make up Emblem, Group Health Inc. and the Health Insurance Plan of Greater New York, and the city has since that time urged state regulators to prevent the combined company from becoming for-profit.

Emblem put its efforts on hold in mid-2008. But the company and state officials in recent months have been preparing to proceed, most likely in an effort to sell Emblem to another insurer, according to several state officials who have been briefed on the matter. A spokeswoman for EmblemHealth declined to comment.

Some lawmakers suggested this month that the Emblem issue had become linked to the tense negotiations between Mr. Cuomo and Mr. Bloomberg over legislation to allow livery cabs to be hailed on most New York City streets. They said they suspected that Mr. Cuomo was holding out approval of the livery deal in an effort to press Mr. Bloomberg into agreeing to drop the city’s resistance to the Emblem deal.

A spokesman for Mr. Cuomo insisted that was not the case. Mr. Cuomo signed the livery cab legislation this week.

“The city has been arguing the same point for five years — if there is an Emblem sale, they want more of the proceeds than the Legislature has previously authorized,” the spokesman, Josh Vlasto, said. “However, the entire issue is irrelevant because there is no potential sale on the horizon.”

A high-ranking state official said Mr. Cuomo’s budget proposal, which he will unveil next month, would not presume any revenue from a possible Emblem deal.

If Emblem does find a buyer, Mr. Bloomberg would have considerable leverage in trying to win concessions from the insurer.

Mr. Bloomberg noted in his radio appearance that Emblem would be worth far less if the city — the insurer’s biggest customer — took its business elsewhere. And the city is keeping its options open; about a month ago, it circulated a request for information from other health insurers as the Bloomberg administration considered seeking other possible providers.

“If we didn’t exist, they would still exist, but they would be worth a lot less in the marketplace,” Mr. Bloomberg said of Emblem. “So that’s why everybody cares, and nobody is going to buy Emblem unless they talk to the city.”

Mr. Bloomberg hinted that it was possible, for example, that as part of a sale, the city would pledge to keep its business with Emblem for a certain period of time. In return, the city might ask Emblem to promise that health insurance rates would not increase more than a certain percent annually.

Harry Nespoli, the chairman of the Municipal Labor Committee, the umbrella group for the city’s public employee unions, said labor leaders had expressed concerns to Mr. Cuomo’s office about how a possible conversion would affect workers’ benefits.

“The exact services that our members have and the structure for our health coverage has to be the same,” Mr. Nespoli said in a telephone interview. “If it’s going to affect our members, we are definitely going to get louder with our voices.”


View the original article here